Beam's Base-Edited Sickle Cell Therapy Meets 12-Month Trial Goal

Beam Therapeutics says its base-edited cell therapy for sickle cell disease met the main goal of its pivotal BEACON trial. The Cambridge, Massachusetts company released the topline results on Nov 10, 2026.

What happened

The drug is ristoglogene autogetemcel, called risto-cel and formerly known as BEAM-101. It is a one-time treatment made from a patient's own blood stem cells, which are edited and then given back through a stem cell transplant.

The main efficacy goal was freedom from severe vaso-occlusive crises, known as VOCs, for at least 12 consecutive months. Beam says the result was based on independently adjudicated data.

• Patients: as of an Oct 20, 2026 data cutoff, 39 adults and 10 adolescents had been treated, and 31 had finished the follow-up needed for the main goal.
• Other goals: the company says the trial met all secondary efficacy goals, including 12 months without a hospital stay for severe crises.
• Safety: Beam says the trial met all primary safety goals at a prespecified interim analysis. It says safety was in line with earlier data and with the known effects of busulfan conditioning and the transplant process.

Beam has not yet shared how many of the 31 patients reached the main goal, as BioPharm International noted. The company did not list individual safety events either.

Why it matters

Beam plans to file a Biologics License Application with the FDA as early as the end of 2026. Its chief executive, John Evans, said it could be the first such filing for a base editing therapy.

The edit targets the promoter regions of the HBG1 and HBG2 genes. Beam says it is designed to block a repressor called BCL11A from binding there and so raise fetal hemoglobin.

If approved, risto-cel would join two therapies the FDA cleared for sickle cell disease in 2023: Vertex's Casgevy and bluebird bio's Lyfgenia, according to BioPharm International. The company puts the number of people with the disease at about 100,000 in the US.

What it means for people in the industry

Beam has not announced any hiring, site plans or staffing changes tied to the results or the planned filing.

Things to watch:

• An oral presentation from an earlier data cutoff at the 68th American Society of Hematology meeting, December 12 to 15 in New Orleans.
• Full pivotal results, which Beam plans to present at a medical meeting in 2027.
• Whether the FDA filing lands by the end of 2026.

See open pharma jobs in the US and Canada

Sources

• Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease, Beam Therapeutics (GlobeNewswire)
• Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial, BioPharm International